The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Academic Article

abstract

• Our understanding of the diagnostic and prognostic use of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has broadly expanded over the past few years. The utilization of ctDNA to detect minimal residual disease is currently being employed across the continuum of cancer care. The lead-time of ctDNA positivity to radiographic recurrence in stage I to III CRC is up to 9 months on average, which provides a therapeutic window for a group of high-risk patients who will ultimately recur. There are several ongoing prospective clinical trials that investigate whether ctDNA can be used as an integral biomarker to risk stratify CRC patients and guide adjuvant treatment decisions. In this review, we summarize the evidence supporting the promise of ctDNA-defined MRD in CRC and highlight the current ctDNA guided adjuvant prospective clinical trials.

authors

• Raghavan, Shreya

published proceedings

• Clin Colorectal Cancer

altmetric score

• 9.25

author list (cited authors)

• Bent, A., Raghavan, S., Dasari, A., & Kopetz, S.

citation count

• 8

complete list of authors

• Bent, Alisha||Raghavan, Shreya||Dasari, Arvind||Kopetz, Scott

publication date

• January 2022

publisher

• Elsevier  Publisher

published in

• Clinical Colorectal Cancer  Journal

keywords

• Biomarkers
• Biomarkers, Tumor
• Circulating Tumor Dna
• Clinical Trials
• Colon Cancer
• Colorectal Neoplasms
• Humans
• Liquid Biopsy
• Neoplasm, Residual
• Prognosis
• Prospective Studies

Digital Object Identifier (DOI)

• 10.1016/j.clcc.2022.03.004

start page

• 89

end page

• 95

volume

• 21

issue

• 2

URL

• http://dx.doi.org/10.1016/j.clcc.2022.03.004